Analyst Review Alert: Franklin Electric Co., Inc. (FELE)

The shares of Franklin Electric Co., Inc. (NASDAQ:FELE) currently has mean rating of 3.00 while 0 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 7 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 256.51M by 7 analysts. The means estimate of sales for the year ending Dec-16 is 948.91M by 8 analysts.

The mean price target for the shares of Franklin Electric Co., Inc. (FELE) is at 33.57 while the highest price target suggested by the analysts is 38.00 and low price target is 26.00. The mean price target is calculated keeping in view the consensus of 7 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Franklin Electric Co., Inc. (FELE) stands at 0.49 while the EPS for the current year is fixed at 1.64 by 7 analysts.

The next one year’s EPS estimate is set at 1.83 by 9 analysts while a year ago the analysts suggested the company’s EPS at 1.64. The analysts also projected the company’s long-term growth at 40.00% for the upcoming five years.

In its latest quarter ended on 31st March 2016, Franklin Electric Co., Inc. (FELE) reported earnings of $0.29. The posted earnings missed the analyst’s consensus by $-0.02 with the surprise factor of -6.50%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Franklin Electric Co., Inc. (FELE) will display the new Fhoton™ SolarPAK system, which utilizes Franklin’s proven solar technology with the new Fhoton solar drive that features a smaller modular design – providing flexibility and simple maintenance for the installer. The new Fhoton solar drive features a robust IP66, NEMA 4 enclosure that protects against wildlife, insects, dust, and weather. The system is available in a variety of flow rates from 2.5 gpm to 90 gpm and power ratings of 0.75 and 1.5 hp. For solar installers looking to partner with a driller, contact Franklin Electric who will connect you with its expansive network of water systems professionals that you can team with.

Stock Grabbing Investor’s Attention: Adamas Pharmaceuticals, Inc. (ADMS)

The shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) currently has mean rating of 1.89 while 1 analysts have recommended the shares as “BUY”, 8 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 210.00K by 7 analysts. The means estimate of sales for the year ending Dec-15 is 730.00K by 9 analysts.

The mean price target for the shares of Adamas Pharmaceuticals, Inc. (ADMS) is at 35.56 while the highest price target suggested by the analysts is 45.00 and low price target is 22.00. The mean price target is calculated keeping in view the consensus of 9 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Adamas Pharmaceuticals, Inc. (ADMS) stands at -0.70 while the EPS for the current year is fixed at -3.09 by 9 analysts.

The next one year’s EPS estimate is set at -2.69 by 8 analysts while a year ago the analysts suggested the company’s EPS at -3.09. The analysts also projected the company’s long-term growth at 79.36% for the upcoming five years.

In its latest quarter ended on 31st March 2016, Adamas Pharmaceuticals, Inc. (ADMS) reported earnings of $-0.65. The posted earnings topped the analyst’s consensus by $0.11 with the surprise factor of 14.50%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 22, 2016 Adamas Pharmaceuticals, Inc. (ADMS) announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD) at the 20th Annual International Congress of Parkinson’s and Movement Disorders in Berlin, Germany.  Data was presented from two trials — EASE LID and EASE LID 2 — by Rajesh Pahwa, M.D., a recognized expert in PD and LID.  Levodopa-induced dyskinesia, which is a condition characterized by involuntary movements without purpose, can become severely disabling, rendering people with Parkinson’s disease unable to perform routine daily tasks.

Analyst’s Report Recap: RAIT Financial Trust (RAS)

The shares of RAIT Financial Trust (NYSE:RAS) currently has mean rating of 2.00 while 3 analysts have recommended the shares as “BUY”, 0 recommended as “OUTPERFORM” and 3 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 25.55M by 4 analysts. The means estimate of sales for the year ending Dec-16 is 103.35M by 4 analysts.

The mean price target for the shares of RAIT Financial Trust (RAS) is at 3.27 while the highest price target suggested by the analysts is 3.75 and low price target is 2.50. The mean price target is calculated keeping in view the consensus of 6 brokerage firms.

The average estimate of EPS for the current fiscal quarter for RAIT Financial Trust (RAS) stands at 0.13 while the EPS for the current year is fixed at 0.55 by 5 analysts.

The next one year’s EPS estimate is set at 0.58 by 6 analysts while a year ago the analysts suggested the company’s EPS at 0.55. The analysts also projected the company’s long-term growth at 13.50% for the upcoming five years.

In its latest quarter ended on 31st March 2016, RAIT Financial Trust (RAS) reported earnings of $0.14. The posted earnings topped the analyst’s consensus by $0.01 with the surprise factor of 7.70%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 15, 2016 RAIT Financial Trust (RAS) announced that on June 15, 2016, RAIT’s Board of Trustees declared a second quarter 2016 cash dividend on RAIT’s common shares of $0.09 per common share. The dividend will be paid on July 29, 2016 to holders of record on July 8, 2016. The ex-dividend date is July 6, 2016.

RAIT Financial Trust is an internally-managed real estate investment trust that provides debt financing options to owners of commercial real estate and invests directly into commercial real estate properties located throughout the United States. In addition, RAIT is an asset and property manager of real estate-related assets.

Stock in Focus Today: LTC Properties Inc. (LTC)

The shares of LTC Properties Inc. (NYSE:LTC) currently has mean rating of 2.55 while 1 analysts have recommended the shares as “BUY”, 3 recommended as “OUTPERFORM” and 7 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 33.57M by 6 analysts. The means estimate of sales for the year ending Dec-16 is 134.93M by 7 analysts.

The mean price target for the shares of LTC Properties Inc. (LTC) is at 51.83 while the highest price target suggested by the analysts is 62.00 and low price target is 46.00. The mean price target is calculated keeping in view the consensus of 6 brokerage firms.

The average estimate of EPS for the current fiscal quarter for LTC Properties Inc. (LTC) stands at 0.77 while the EPS for the current year is fixed at 3.09 by 9 analysts.

The next one year’s EPS estimate is set at 3.23 by 10 analysts while a year ago the analysts suggested the company’s EPS at 3.09. The analysts also projected the company’s long-term growth at 4.00% for the upcoming five years.

In its latest quarter ended on 31st March 2016, LTC Properties Inc. (LTC) reported earnings of $0.76. The posted earnings topped the analyst’s consensus by $0.01 with the surprise factor of 1.30%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 14, 2016 LTC Properties Inc. (LTC) announced that it locked rate under a private shelf agreement with an insurance company on $40.0 million of senior unsecured notes with a coupon of 3.99%. The notes will have an average 10-year life, scheduled principal payments and will mature in 2031. LTC anticipates selling the notes on or about July 20, 2016.

LTC is a self-administered real estate investment trust that primarily invests in senior housing and long-term care properties through triple-net lease transactions, mortgage loans and other investments. For more information on LTC Properties, Inc., visit the Company’s website at www.LTCreit.com.

Analysts Estimations: Amedica Corporation (AMDA)

The shares of Amedica Corporation (NASDAQ:AMDA) currently has mean rating of 1.00 while 1 analysts have recommended the shares as “BUY”, 0 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 5.16M by 1 analysts. The means estimate of sales for the year ending Dec-16 is 20.21M by 1 analysts.

The mean price target for the shares of Amedica Corporation (AMDA) is at 5.00 while the highest price target suggested by the analysts is 5.00 and low price target is 5.00. The mean price target is calculated keeping in view the consensus of 1 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Amedica Corporation (AMDA) stands at -0.25 while the EPS for the current year is fixed at -1.04 by 1 analysts.

The next one year’s EPS estimate is set at -0.81 by 1 analysts while a year ago the analysts suggested the company’s EPS at -1.04.

In its latest quarter ended on 31st March 2016, Amedica Corporation (AMDA) reported earnings of $-0.30. The posted earnings missed the analyst’s consensus by $-0.05 with the surprise factor of -20.00%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 13, 2016 Amedica Corporation (AMDA) announced that it has submitted its responses to the Food and Drug Administration (FDA) in relation to the CASCADE clinical trial.

The CASCADE study compared the 24-month outcomes from single-level cervical fusion between Amedica’s porous silicon nitride versus bone autograft. Data showed that porous silicon nitride achieved clinical and radiographic outcomes that were comparable to bone autograft.

“Porous silicon nitride is a synthetic platform that can achieve spinal fusion without added bone graft, based on the results of our clinical trial,” said Dr. Sonny Bal, chairman and CEO of Amedica Corporation. “These outcomes are consistent with our understanding of the surface chemistry and nano-topography of silicon nitride. We believe the composite porous silicon nitride fusion device used in the CASCADE trial, if approved by the FDA, will improve patient health. We are confident that we have addressed the questions raised by the FDA.”

Stock to Watch: MACOM Technology Solutions Holdings, Inc. (MTSI)

The shares of MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI) currently has mean rating of 1.64 while 4 analysts have recommended the shares as “BUY”, 7 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 140.02M by 10 analysts. The means estimate of sales for the year ending September-16 is 537.03M by 10 analysts.

The mean price target for the shares of MACOM Technology Solutions Holdings, Inc. (MTSI) is at 48.82 while the highest price target suggested by the analysts is 52.00 and low price target is 44.00. The mean price target is calculated keeping in view the consensus of 11 brokerage firms.

The average estimate of EPS for the current fiscal quarter for MACOM Technology Solutions Holdings, Inc. (MTSI) stands at 0.51 while the EPS for the current year is fixed at 1.95 by 10 analysts.

The next one year’s EPS estimate is set at 2.65 by 10 analysts while a year ago the analysts suggested the company’s EPS at 1.95. The analysts also projected the company’s long-term growth at 20.60% for the upcoming five years.

In its latest quarter ended on 31st March 2016, MACOM Technology Solutions Holdings, Inc. (MTSI) reported earnings of $0.46. The posted earnings topped the analyst’s consensus by $0.02 with the surprise factor of 4.50%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 14, 2016 MACOM Technology Solutions Holdings, Inc. (MTSI) announced the new MAAP-011161 and the MAAP-011193, two packaged linear power amplifiers designed specifically for use in point to point radios in cellular backhaul applications. The MAAP-011161 and MAAP-011193 operate over 7.1-7.9 GHz and 7.7-8.5 GHz respectively, and are intended for 7 and 8 GHz radio applications.

The MAAP-011161 and MAAP-011193 feature a Third Order Intercept Point (OIP3) of 46.5 dBm and greater than 35.5 dBm saturated output power. The MAAP-011161 boasts 22 dB small signal gain, while the MAAP-011193 provides 20 dB small signal gain. These power amplifier MMICs come in an air cavity 7 mm surface mount package with a copper coin paddle for excellent thermal performance. The devices include on-chip ESD protection structures and DC by-pass capacitors to ease the implementation and volume assembly of the packaged part, and are RoHS Compliant.

Stock under Consideration: Abeona Therapeutics Inc. (ABEO)

The shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) currently has mean rating of 1.80 while 1 analysts have recommended the shares as “BUY”, 4 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 240.00K by 3 analysts. The means estimate of sales for the year ending Dec-16 is 980.00K by 3 analysts.

The mean price target for the shares of Abeona Therapeutics Inc. (ABEO) is at 12.63 while the highest price target suggested by the analysts is 17.00 and low price target is 6.00. The mean price target is calculated keeping in view the consensus of 4 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Abeona Therapeutics Inc. (ABEO) stands at -0.15 while the EPS for the current year is fixed at -0.59 by 3 analysts.

The next one year’s EPS estimate is set at -0.42 by 3 analysts while a year ago the analysts suggested the company’s EPS at -0.59.

In its latest quarter ended on 31st March 2016, Abeona Therapeutics Inc. (ABEO) reported earnings of $-0.17. The posted earnings missed the analyst’s consensus by $-0.04 with the surprise factor of -30.38%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On May 24, 2016 Abeona Therapeutics Inc. (ABEO) announced the FDA has allowed an Investigational New Drug (IND) Application for its Phase 1/2 Clinical Study with gene therapy candidate ABO-101 (AAV-NAGLU) for patients with Sanfilippo syndrome type B (MPS IIIB) to be conducted at Nationwide Children’s Hospital (Columbus, OH). This is the second FDA allowance for a gene therapy trial from Abeona this year, following allowance of an IND in February for ABO-102, for patients with MPS IIIA which commenced with dosing of the first cohort of patients this month.

Stock to Watch: Central Pacific Financial Corp. (CPF)

The shares of Central Pacific Financial Corp. (NYSE:CPF) currently has mean rating of 2.60 while 0 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 3 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 44.04M by 5 analysts. The means estimate of sales for the year ending Dec-16 is 177.53M by 5 analysts.

The mean price target for the shares of Central Pacific Financial Corp. (CPF) is at 24.20 while the highest price target suggested by the analysts is 25.00 and low price target is 23.00. The mean price target is calculated keeping in view the consensus of 5 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Central Pacific Financial Corp. (CPF) stands at 0.35 while the EPS for the current year is fixed at 1.45 by 5 analysts.

The next one year’s EPS estimate is set at 1.53 by 5 analysts while a year ago the analysts suggested the company’s EPS at 1.45. The analysts also projected the company’s long-term growth at 8.00% for the upcoming five years.

In its latest quarter ended on 31st March 2016, Central Pacific Financial Corp. (CPF) reported earnings of $0.35. The posted earnings topped the analyst’s consensus by $0.02 with the surprise factor of 6.10%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On April 28, 2016 Central Pacific Financial Corp. (CPF) reported net income for the first quarter of 2016 of $11.2 million, or $0.35 per diluted share, compared to net income in the first quarter of 2015 of $10.4 million, or $0.29 per diluted share, and net income in the fourth quarter of 2015 of $10.9 million, or $0.34 per diluted share.

During the first quarter of 2016, the Company repurchased 233,722 shares of common stock, or approximately 0.7% of its common stock outstanding as of December 31, 2015, at a total cost of $4.7 million. The Company’s remaining repurchase authority under its common stock repurchase program at March 31, 2016 is $25.3 million.

On April 27, 2016, the Company’s Board of Directors declared a quarterly cash dividend of $0.14 per share on the Company’s outstanding common shares. The dividend will be payable on June 15, 2016 to shareholders of record at the close of business on May 31, 2016.

Featured Stock: Coherent Inc. (COHR)

The shares of Coherent Inc. (NASDAQ:COHR) currently has mean rating of 1.50 while 2 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 211.94M by 5 analysts. The means estimate of sales for the year ending September-16 is 836.67M by 5 analysts.

The mean price target for the shares of Coherent Inc. (COHR) is at 113.20 while the highest price target suggested by the analysts is 116.00 and low price target is 105.00. The mean price target is calculated keeping in view the consensus of 5 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Coherent Inc. (COHR) stands at 1.11 while the EPS for the current year is fixed at 4.54 by 4 analysts.

The next one year’s EPS estimate is set at 6.08 by 4 analysts while a year ago the analysts suggested the company’s EPS at 4.54. The analysts also projected the company’s long-term growth at -10.00% for the upcoming five years.

In its latest quarter ended on 31st March 2016, Coherent Inc. (COHR) reported earnings of $1.04. The posted earnings topped the analyst’s consensus by $0.05 with the surprise factor of 5.10%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On April 28, 2016 Coherent Inc. (COHR) announced financial results for its second fiscal quarter ended April 2, 2016.

SECOND FISCAL QUARTER DETAILS

For the second fiscal quarter ended April 2, 2016, Coherent announced net sales of $199.9 million and net income, on a U.S. generally accepted accounting principles (GAAP) basis, of $17.8 million, or $0.73 per diluted share.  These results compare to net sales of $203.7 million and net income of $18.4 million, or $0.74 per diluted share, for the second quarter of fiscal 2015.

Non-GAAP net income for the second quarter of fiscal 2016 was $25.3 million, or $1.04 per diluted share.  Non-GAAP net income for the second quarter of fiscal 2015 was $23.4 million, or $0.94 per diluted share. Reconciliations of GAAP to non-GAAP financial measures for the three months ended April 2, 2016, January 2, 2016 and April 4, 2015 appear in the financial statements portion of this release under the heading “Reconciliation of GAAP to Non-GAAP net income.”

Net sales for the first quarter of fiscal 2016 were $190.3 million and net income, on a GAAP basis, was $20.3 million, or $0.84 per diluted share. Non-GAAP net income for the first quarter of fiscal 2016 was $23.9 million, or $0.99 per diluted share.

Analyst’s Report Recap: Alcoa Inc (NYSE:AA)

The shares of Alcoa Inc (NYSE:AA)currently has mean rating of 2.4 while 6 analyst have recommended the shares as ‘BUY’ ,3 recommended as ‘OUTPERFORM’ and 8 recommended as ‘HOLD’.The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell

The mean price target for the shares of Alcoa Inc (NYSE:AA)is at $10.82 while the highest price target suggested by the analysts is $15.00 and low price target is $7.00. The mean price target is calculated keeping in view the consensus of 14 brokerage firms.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 5.18B by 11 analysts. The means estimate of sales for the year ending Dec 16 is 20.67B by 17 analysts.

The average estimate of EPS for the current fiscal quarter for Alcoa Inc (NYSE:AA)stands at $0.09 while the EPS for the current year is fixed at $0.36 by 14.00 analysts

The next one year’s EPS estimate is set at 0.54 by 17.00 analysts while a year ago the analysts suggested the company’s EPS at $0.36. The analysts also projected the company’s long-term growth at 12.65% for the upcoming five years

In its latest quarter ended on 31 Mar 2016 , Alcoa Inc (NYSE:AA)reported earnings of $0.07. The posted earnings topped the analyst’s consensus by $0.05 with the surprise factor of 250.00%. In the matter of earnings surprises, the term ‘Cockroach Effect’ is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Alcoa Inc (NYSE:AA) traded up +2.63% during trading on Friday, hitting $10.17 . The stock had a trading volume of 20.5 M shares. The firm has a 50 day moving average of $9.52 and a 200-day moving average of $9.15. The stock has a market cap of $13.35B. On Jun 26, 2015 the shares registered one year high at $11.77 and the one year low was seen on Jan 20, 2016.

On June 22, 2016 Alcoa Inc (NYSE:AA) will host a webcast on Wednesday, June 29, at 8:30 a.m. EDT to discuss the contents of the initial filing with the Securities and Exchange Commission of the Registration Statement on Form 10 expected at approximately 7 a.m. EDT that day. The filing of the Form 10 is an important milestone in the Company’s plan to separate into two independent, publicly-traded companies.

The conference call will be webcast live via Alcoa’s website at www.alcoa.com. The Form 10 and presentation materials will be available online at approximately 7 a.m. EDT at www.Alcoa.com/form_10_presentation.

Conference Call Information

Time:8:30 a.m. EDT – 9:30 a.m. EDT

Hosts:Klaus Kleinfeld, Chairman and Chief Executive Officer

William Oplinger, Executive Vice President and Chief Financial Officer

Call:(855) 252-9433

+ 1 (484) 487-2715

Conference ID: 31439151

to avoid delay to the start time, please dial-in beginning at 8:15 a.m.